Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
| ▸ | CHI3L1 | P36222 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | CHIT1 | Q13231 | 1/20 | 0.33 |
| ▸ | CHIA | Q9BZP6 | 1/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1490003 | 0.82 | CYP2D6 (0.35) | KCNH2PIK3CD | |
| SCHEMBL1490132 | 0.80 | NSD2 (0.30) | — | |
| SCHEMBL22200610 | 0.78 | SLC6A2 (0.37) | SLC6A2SLC6A4CHI3L1KCNH2CHIT1 | |
| SCHEMBL24429364 | 0.77 | SLC6A2 (0.36) | SLC6A2SLC6A4CHI3L1KCNH2CHIT1 | |
| SCHEMBL1490009 | 0.76 | DRD3 (0.43) | — | |
| SCHEMBL22200611 | 0.75 | SLC6A2 (0.35) | SLC6A2SLC6A4CHI3L1KCNH2CHIT1 | |
| SCHEMBL21038725 | 0.75 | SLC6A2 (0.55) | SLC6A2SLC6A4KCNH2CHIT1CHIA | |
| SCHEMBL24429366 | 0.75 | SLC6A2 (0.35) | SLC6A2SLC6A4CHI3L1KCNH2CHIT1 | |
| SCHEMBL18248893 | 0.75 | SLC6A2 (0.38) | SLC6A2SLC6A4CHI3L1KCNH2CHIT1 | |
| SCHEMBL14160972 | 0.75 | ALDH1A1 (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7112594-B2 | Fused bicyclic amide compounds and medicinal use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2006-09-26 | — | — | US | disclosed |
| US-7015218-B1 | Amide compounds and medicinal use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2006-03-21 | — | — | US | disclosed |
| EP-1176140-B1 | AMIDE COMPOUNDS AND MEDICINAL USE THEREOF | MITSUBISHI PHARMA CORP (JP) | 2004-12-29 | — | — | EP | disclosed |
| US-20030203909-A1 | Fused bicyclic amide compounds and medicinal use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2003-10-30 | — | — | US | disclosed |
| EP-1310488-A1 | FUSED BICYCLIC AMIDE COMPOUNDS AND MEDICINAL USE THEREOF | Mitsubishi Pharma Corporation (JP) | 2003-05-14 | — | — | EP | disclosed |
| EP-1176140-A1 | AMIDE COMPOUNDS AND MEDICINAL USE THEREOF | Mitsubishi Pharma Corporation (JP) | 2002-01-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030203909-A1 | Fused bicyclic amide compounds and medicinal use thereof | BET1, NFATC1, ARG1 | SLC6A2 4109/4885SLC6A4 3848/4885CHI3L1 1228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.